BIOMAT Database Logo BIOMAT Database Logo

Transfusion-related problems following major ABO-incompatible bone marrow transplantation. 2003

Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Department of Clinical Pathology, Iwate Medical University 19-1, Uchimaru, Iwate 020-8505, Morioka City, Japan. ttasaki@iwate-med.ac.jp <ttasaki@iwate-med.ac.jp>

A case of acute myelocytic leukemia has been reported in which the patient's surviving original B lymphocytes after pretransplant-conditioning chemotherapy probably reproduced hemagglutinins that reacted with red blood cells (RBCs) derived from engrafted donor marrow for a prolonged period of time. Although the direct antiglobulin test was negative and hemagglutinins were not detectable in the patient's sera but only in the eluate, the antibodies reappeared in the sera. Therefore, it is important to confirm that the eluate does not contain antibodies that would react with donor-derived RBCs when the type of red cell used for transfusion is switched from the patient's type to the donor's type in a major ABO-mismatched bone marrow transplantation (BMT). Testing of ABO subgroups using lectins is also recommended to avoid a delayed hemolytic transfusion reaction following BMT.

UI MeSH Term Description Entries
D007518 Isoantibodies Antibodies from an individual that react with ISOANTIGENS of another individual of the same species. Alloantibodies
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001787 Blood Group Incompatibility An antigenic mismatch between donor and recipient blood. Antibodies present in the recipient's serum may be directed against antigens in the donor product. Such a mismatch may result in a transfusion reaction in which, for example, donor blood is hemolyzed. (From Saunders Dictionary & Encyclopedia of Laboratory Medicine and Technology, 1984). ABO Compatibility,ABO Incompatibility,Blood Group ABO Incompatibility,Blood Type Incompatibility,Rh Compatibility,Rh Incompatibility,ABO Compatibilities,ABO Incompatibilities,Blood Group Incompatibilities,Blood Type Incompatibilities,Compatibility, ABO,Compatibility, Rh,Incompatibilities, Blood Group,Incompatibility, ABO,Incompatibility, Blood Group,Incompatibility, Blood Type,Incompatibility, Rh,Rh Compatibilities,Rh Incompatibilities
D004912 Erythrocytes Red blood cells. Mature erythrocytes are non-nucleated, biconcave disks containing HEMOGLOBIN whose function is to transport OXYGEN. Blood Cells, Red,Blood Corpuscles, Red,Red Blood Cells,Red Blood Corpuscles,Blood Cell, Red,Blood Corpuscle, Red,Erythrocyte,Red Blood Cell,Red Blood Corpuscle
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000017 ABO Blood-Group System The major human blood type system which depends on the presence or absence of two antigens A and B. Type O occurs when neither A nor B is present and AB when both are present. A and B are genetic factors that determine the presence of enzymes for the synthesis of certain glycoproteins mainly in the red cell membrane. ABH Blood Group,ABO Blood Group,ABO Factors,Blood Group H Type 1 Antigen,H Blood Group,H Blood Group System,ABO Blood Group System,Blood Group, ABH,Blood Group, ABO,Blood Group, H,Blood-Group System, ABO,Factors, ABO,System, ABO Blood-Group
D015470 Leukemia, Myeloid, Acute Clonal expansion of myeloid blasts in bone marrow, blood, and other tissue. Myeloid leukemias develop from changes in cells that normally produce NEUTROPHILS; BASOPHILS; EOSINOPHILS; and MONOCYTES. Leukemia, Myelogenous, Acute,Leukemia, Nonlymphocytic, Acute,Myeloid Leukemia, Acute,Nonlymphocytic Leukemia, Acute,ANLL,Acute Myelogenous Leukemia,Acute Myeloid Leukemia,Acute Myeloid Leukemia with Maturation,Acute Myeloid Leukemia without Maturation,Leukemia, Acute Myelogenous,Leukemia, Acute Myeloid,Leukemia, Myeloblastic, Acute,Leukemia, Myelocytic, Acute,Leukemia, Myeloid, Acute, M1,Leukemia, Myeloid, Acute, M2,Leukemia, Nonlymphoblastic, Acute,Myeloblastic Leukemia, Acute,Myelocytic Leukemia, Acute,Myelogenous Leukemia, Acute,Myeloid Leukemia, Acute, M1,Myeloid Leukemia, Acute, M2,Nonlymphoblastic Leukemia, Acute,Acute Myeloblastic Leukemia,Acute Myeloblastic Leukemias,Acute Myelocytic Leukemia,Acute Myelocytic Leukemias,Acute Myelogenous Leukemias,Acute Myeloid Leukemias,Acute Nonlymphoblastic Leukemia,Acute Nonlymphoblastic Leukemias,Acute Nonlymphocytic Leukemia,Acute Nonlymphocytic Leukemias,Leukemia, Acute Myeloblastic,Leukemia, Acute Myelocytic,Leukemia, Acute Nonlymphoblastic,Leukemia, Acute Nonlymphocytic,Leukemias, Acute Myeloblastic,Leukemias, Acute Myelocytic,Leukemias, Acute Myelogenous,Leukemias, Acute Myeloid,Leukemias, Acute Nonlymphoblastic,Leukemias, Acute Nonlymphocytic,Myeloblastic Leukemias, Acute,Myelocytic Leukemias, Acute,Myelogenous Leukemias, Acute,Myeloid Leukemias, Acute,Nonlymphoblastic Leukemias, Acute,Nonlymphocytic Leukemias, Acute
D016026 Bone Marrow Transplantation The transference of BONE MARROW from one human or animal to another for a variety of purposes including HEMATOPOIETIC STEM CELL TRANSPLANTATION or MESENCHYMAL STEM CELL TRANSPLANTATION. Bone Marrow Cell Transplantation,Grafting, Bone Marrow,Transplantation, Bone Marrow,Transplantation, Bone Marrow Cell,Bone Marrow Grafting
D019653 Myeloablative Agonists Agents that destroy bone marrow activity. They are used to prepare patients for BONE MARROW TRANSPLANTATION or STEM CELL TRANSPLANTATION. Myeloablative Agonist,Agonist, Myeloablative,Agonists, Myeloablative

Related Publications

Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Major ABO incompatible bone marrow transplantation.
April 1980, Haematologica,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Isoagglutinins following ABO-incompatible bone marrow transplantation.
January 1992, Vox sanguinis,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
ABO-incompatible bone marrow transplantation: the transfusion of incompatible plasma may exacerbate regimen-related toxicity.
January 1999, Transfusion,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
ABO-incompatible bone marrow transplantation.
January 1992, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Immunohematologic problems arising from ABO incompatible bone marrow transplantation.
December 1987, Transplantation proceedings,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Efficacy of cryofiltration in major ABO-incompatible bone marrow transplantation.
December 1987, Transplantation proceedings,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
[ABO-incompatible allogeneic bone marrow transplantation].
August 1999, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Severe delayed hemolytic transfusion reaction complicating an ABO-incompatible bone marrow transplantation.
January 1983, Vox sanguinis,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
[Erythrocyte substitution and isoagglutinin titer following ABO-incompatible bone marrow transplantation].
January 1990, Beitrage zur Infusionstherapie = Contributions to infusion therapy,
Tetsunori Tasaki, and Shyukuko Satoh, and Kenji Gotoh, and Kieko Fujii, and Sakiko Sasaki, and Junko Takadate, and Mihoko Tachibana, and Yoko Ono, and Yoji Ishida
Erythrocyte repopulation after major ABO incompatible transplantation with lymphocyte-depleted bone marrow.
December 1995, Bone marrow transplantation,
Copied contents to your clipboard!